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Abstract. Leishmaniasis is a vector-borne disease caused by protozoan parasites of the Leishmania genus. In Australia,
leishmaniasis is an imported disease that is presenting itself at increased rates because of international travel, the influx of
immigrants, and deployment of military operations to endemic regions. Although Leishmania species are morphologically
indistinguishable, there is a strong correlation between some causative species of leishmaniasis and the subsequent re-
sponse to the treatmentsavailable andpatient outcome.Consequently, identificationof the infective species is imperative as
misidentificationcan result in theadministeringofan ineffectivedrug.Theaimof this studywas todevelopasimplediagnostic
tool with high sensitivity and specificity, which is capable of detecting the presence of the parasite and accurately differ-
entiating the causative species in question. Using the advantageous properties of the maxi-circle kinetoplast DNA, a poly-
merase chain reaction (PCR)-restriction fragment lengthpolymorphism (RFLP) targeting theND7genewasdeveloped for the
analysis of imported cases of human leishmaniasis in Australia. Designed as a dual analysis, concurrent PCR of Leishmania
maxi-circle DNA and digestion with two separate enzymes (NlaIII and HpyCH4IV), this study provides an appraisal on 24
imported cases of leishmaniasis between 2008 and 2017. Five Leishmania species were reported, with members of the
Viannia subgenusbeing themost common. The implementationof novel diagnostic procedures for leishmaniasis suchas the
one reported here is needed to establish a gold standard practice for the diagnosis and treatment of leishmaniasis.
INTRODUCTION
Leishmaniasis is a complex disease with a global distribu-
tion, affecting approximately 12 million people and a further
350 million at risk of contracting the disease.1 Leishmania in-
fections manifest as three distinct clinical forms of leishman-
iasis depending on the species in question and location of
infection: cutaneous leishmaniasis (CL), mucocutaneous
leishmaniasis (MCL), and visceral leishmaniasis (VL or kala-
azar). This broad-spectrum disease can manifest from either
zoonotic or anthroponotic transmission. Zoonotic leishmani-
asis tends to occur in rural settings across endemic regions,
whereas anthroponotic leishmaniasis tends to occur in
densely populated urban regions.1,2 Species of the Leish-
mania (Viannia) (L. [V.]) subgenus are restricted to the Neo-
tropics (New World), whereas the subgenus Leishmania
(Leishmania) (L. [L.]) occurs in both the New World and Old
World (Figure 1). Representing a major public health problem,
in the absence of a “gold standard” or reference biomarker, a
widearray of laboratorymethodshasbeendevelopedover the
last 20 years for the diagnosis of leishmaniasis.3–10 Tradi-
tionally, diagnosis was based primarily on clinical manifesta-
tions of the disease and the microscopic detection of
Leishmania parasites.11 The obvious drawback to this tech-
nique is that the sensitivity is dependent on the skill of the
technician with reported sensitivities ranging from 43% to
85%.12–14 As such, conventional methods involving parasi-
tological and serological detection are now routinely used for
the examination of stained biopsy smears and identification of
infected reservoir hosts, respectively.15 Although useful for
patient diagnosis, limitations surrounding these conventional
methods and their ability to definitively identify the species
causing the infection are unfavorable and detrimental to dis-
ease treatment and patient outcome.
Accurate speciation in clinical cases of leishmaniasis is cru-
cial for an effective diagnosis of the disease. Furthermore, re-
search has revealed a link between some Leishmania spp. and
1) severity and clinical outcome of the disease and 2) treatment
outcome.16 Consequently, knowledge of the aetiological agent
causing an infection is necessary to choose the correct course
of chemotherapeutic drugs. A focused treatment chosen as a
result of species identification will work more effectively in the
first instance, avoiding the administering of an ineffective drug,
which are also highly toxic substances. Diagnostics based on
the analyses of DNA sequences offers the most direct and
accurate approach for the identification and discrimination
between species at the taxonomic level.11 Advancements in
molecular biology have revolutionized the genetic approach to
trypanosomatid identification, allowing relatively straightfor-
ward and simple analyses to reveal the true genotypic rela-
tionships between closely related organisms.17
The polymerase chain reaction (PCR) allows rapid isolation,
amplification, and sequencing of DNA samples.11 In recent
years, the conventional PCR has been widely applied for the
diagnosis of diseases caused by the Trypanosomatidae in-
cludingChagas disease, humanAfrican trypanosomiasis, and
leishmaniasis. Copious gene markers including the small
subunit (SSU) rDNA, internal transcribed spacer 1 (ITS1), heat-
shock protein 70 (Hsp70), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) genes have been routinely targeted
for the identification of Leishmania and closely related trypa-
nosomatid species.18 Furthermore, PCR assays have been
developed for the specific diagnosis of all three clinical man-
ifestations of leishmaniasis, including CL, MCL, and VL.19
Polymerase chain reaction–based diagnostics from CL or
MCL samples have high sensitivity (87–98%) and specificity
(³ 84%), enabling rapid detection and the potential for speci-
ation.15 This technique allows for the diagnosis and identifi-
cation of the infective species before the administration of
therapeutic drugs and has shown to be a superior method in
sensitivity and specificity than the conventional diagnostics
involvingmicroscopy andparasite culture.16 It is of paramount
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importance to equip health systems with a simple diagnostic
tool with high sensitivity and specificity, which is capable of
detecting the presence of the parasite and accurately differ-
entiating the causative Leishmania spp. in question. However,
assays that allow simultaneous multispecies testing are per-
haps the most applicable in a laboratory setting and is a cur-
rent trend appearing in diagnostic laboratories.
Residing in the class Kinetoplastida, species of the genus
Leishmania are characterized by the presence of a large,
catenated network of DNA circles that are organized into a
disk-shaped structure known as the kinetoplast.20,21 It is
composed of approximately 10,000 minicircles and 20–50
maxicircles that form the intricate network of the kinetoplast
DNA (kDNA).22–25 In a previous publication, we demonstrated
the importance of the maxicircle for the taxonomic and phy-
logenetic analyses of Leishmania spp., providing a superior
model to improve the resolution of trypanosomatid system-
atics.26 Thus, using the advantageous properties of the maxi-
circle (i.e., potential to discriminate between closely related
species) in the development, a quick and reliable test in the
form of a PCR-RFLP has a clear potential in a laboratory set-
ting. PCR-RFLP detects the variation between the band pat-
terns of the DNA fragments produced through the digestion of
PCR amplicons with specific restriction enzymes.27 Universal
primers targeting a specificmarker for all Leishmania spp. and
an assay that does not require prior gel purification are the
ideal requirements of any future diagnostic technique. The
PCR-RFLPmolecularmethodcombines the sensitivity ofPCR
with the means of species differentiation without additional
sequencing for the diagnosis and identification of Leishmania
species. In addition, when RFLP is linked with PCR, only
nanogram volumes of parasite DNA are required for analysis
compared with that of conventional RFLP methods requiring
micrograms of relatively high-quality DNA.11 Despite the de-
velopment of more updated methods in a diagnostic labora-
tory setting and in the absence of a cost-effective alternative
that can offer an efficient turn-around time from collection to
diagnosis, the PCR-RFLP remains a useful method for the
detection and identification of Leishmania species. Presently,
the protocol described by Schönian et al.8 targeting the ITS
region is themost frequented and citedPCR-RFLP used in the
diagnosis of leishmaniasis. Through RFLP, the amplicon is
digested without prior purification and is able to identify al-
most all pathogenic Leishmania species. This is extremely
useful in a diagnostic setting, allowing rapid and direct iden-
tification of the infection-causing species.28 Despite its prac-
tical usefulness, the key phrase “almost all” is problematic,
demonstrating the limitations of ITS-1 as a genetic marker for
the determination of the pathogenic Leishmania species. This
PCR-RFLP cannot differentiate between closely related spe-
cies within the (L. [V.]) braziliensis complex (L. [V.] and brazil-
iensis/L. [V.] guyanensis/L. [V.] panamensis) and difficulties
arise with the L. (L.) donovani complex (L. [L.] donovani/L. [L.]
infantum).29 When analyzing L. (L.) donovani and L. (L.) infan-
tum using the ITS1-PCR, the restriction pattern is extremely
similar, with only minor variations seen when comparing the
twospecies alongsideoneanother. Subsequently,without the
concurrent digestion of these two species for reference, they
cannot be differentiated. Furthermore, as with minicircles of
the kDNA, the ITS-1 of Leishmania is a heterogeneous multi-
copy gene, which varies greatly in copy number.29 Because of
its heterogeneous nature, sequencing of the ITS1 to correctly
FIGURE 1. World map of geographical distribution of clinically important, human-infecting Leishmania species. Travel history is an important
factor in diagnosing leishmaniasis. This diagram illustrates the epidemiological pattern of various NewWorld (the Americas) and OldWorld (Africa,
Asia, and Europe) Leishmania species. This is particular important in non-endemic areas where any species of Leishmania can be imported from
areas where more than one species is found.
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delineate between species that cannot be differentiated by
RFLP is complicated, requiring laborious and time-consuming
molecular techniques such as cloning of the PCR products.
Thus, although conducive to a high degree of sensitivity, the
heterogeneous nature is not favorable as a target for DNA-
based molecular detection and identification.
In Australia, cases of imported human leishmaniasis are
increasing at an alarming rate because of international travel,
the influx of immigrants, and military operations.29,30 Cuta-
neous leishmaniasis is the most common disease encoun-
tered, with 93%of cases reported since 2005, presentingwith
severe lesions affecting the skin. Visceral leishmaniasis was
reported in the remaining 7% of patients, with no cases of
MCL yet encountered.29,30 This influx highlights the need to
provide diagnostic services and the difficulties present, par-
ticularly with imported cases in Australia in distinguishing
between Leishmania and closely related species. In this study,
we describe a universal PCR assay targeting the ND7 gene
of the kDNA for the accurate diagnosis and identification
of the principal Leishmania spp. associated with clinical
leishmaniasis.
MATERIALS AND METHODS
Subjects and sample collection. Cultured promastigotes
of L. (L.) tropica, L. (L.)major, and L. (V.) braziliensiswere used
for the preliminary analyses in this study. Extracted DNA from
the biopsies of positive cases of imported leishmaniasis were
provided by the Microbiology Department of St. Vincent’s
Hospital, Sydney. All positive cases had been previously di-
agnosed using the ITS1 PCR-RFLP described by Schönian
et al.8 Samples from 24 Leishmania-infected individuals were
used to assess the performance of the PCR-RFLP, targeting
the kDNA in the diagnosis of leishmaniasis. This panel was
composed of samples from across the globe where leish-
maniasis is endemic.
DNA extraction of Leishmania cultures. Cultures of
Leishmania were first cultured on Novy-MacNeal-Nicolle
(NNN) slopes and subsequently transferred to Minimum Es-
sential Medium with 20% fetal calm serum.31 Parasite cultures
were centrifuged at 4,000 × g for 15 minutes to pellet the par-
asite cells. The supernatant was removed and cell pellets were
resuspended in 1,000 μL DNA extraction buffer (0.2 M Tris-
HCL, 0.025 M ethylenediaminetetraacetic acid (EDTA), 0.5%
EDTA, 0.25MNaCl, and 0.3mg/mL proteinase K) and followed
by incubation overnight at 55C. Samples were spun at 4,000 ×
g for 3minutes and the supernatant was removedwith care to a
new tube so as to not disrupt the pellet. The cells were then
subject to DNA extraction using a phenol–chloroform extrac-
tion. Briefly, 500 μL of phenol was added to the lysate and
vortexed for approximately 1 minute. Next, 500 μL of chloro-
form was added and vortexed for an additional minute. The
mixture was then centrifuged at 13,000 × g for 1 minute. The
aqueous layer was carefully removed and extracted twicemore
with phenol and chloroform, as previously described. This was
followed by a final extraction of the aqueous phase once more
with 500μLof chloroform.DNAwas thenprecipitatedovernight
at −20C with the addition of 8 μL 5 M NaCl and 1× volume
isopropanol. The tubes were centrifuged at 13,000 × g for 15
minutes to pellet the DNA.Once the supernatantwas removed,
the pellet was rinsed 3× with 1 mL of 70% ethanol. Once dec-
anted, the DNA pellet was air-dried for 10 minutes at room
temperature and eluted in a total volume of 50 μL ddH2O. All
DNA templates were stored at−20C until assayed.
Variant calling. To assess the suitability of the maxicircle
coding region, a Burrows-Wheeler Alignment tool, was used
to align whole genome sequence reads of various Leishmania
spp. against the reference of each respective species.32
SAMtools and VarScan were then used to identify and filter
variants in the form of single nucleotide polymorphisms
(SNPs) and indels.33,34 The location of SNPs between the
various Leishmania spp. was plotted to investigate the distri-
bution of polymorphisms between species and to determine if
a particular gene might represent an ideal candidate for the
discrimination of Leishmania through an RFLP analysis. A
detailed description of the SNPs distribution throughout the
maxicircle can be found in Supplemental File 1. Species of the
Viannia subgenus: L. (V.) braziliensis/L. (V.) peruviana and L.
(V.) guyanensis/L. (V.) panamensis, and the Leishmania sub-
genus: L. (L.) infantum/L. (L.) donovani were chosen as they
show very little genetic distance between species within their
respective pairs. These species were hypothesized to exhibit
very little variation in their restriction patterns and so variant
calling was performed to identify “hot-spots” that could dis-
criminate between these closely related species. Leishmania
major, Leishmania amazonensis, and Leishmania mexicana
were also selected as they represent well-defined species,
whose taxonomic validity has not come under scrutiny.
Polymerase chain reaction amplification and sensitivity.
Primers were designed to amplify theND7 gene of Leishmania
kDNAproducing fragments of approximately 800bp. ThePCR
mixtures were prepared in a final volume of 50 μL with ND7-F
(GTGCATTTATGCGTTTATTAATGTG) and ND7-R (ACAA-
CATCAACATTACCAATAACTGC). The reaction was carried
out in a final volume of 50 μL using reagents provided in the
MyTaq PCR Kit (Bioline, London, UK) in the following quanti-
ties: 10 μL 5 ×MyTaq reaction buffer, 1 μL 10 μMeach primer,
1 μL MyTaq DNA Polymerase, 1 μL bovine serum albumin
(BSA), and 10–100 ng of DNA. Reactionswere carried out with
an initial denaturation step at 95C for 5 minutes, followed by
39 cycles at 95C for 1 minute, 59C for 1 minute, 72C for 1
minute, and a final extension step at 72C for 5 minutes. To
confirm successful amplification, 4μL of the PCRproductwas
subjected to electrophoresis on 2% agarose gel stained with
GelRed™ Nucleic Acid Gel Stain Biotium (Fremont, CA). The
ND7 PCR was performed on the DNA extracted directly from
the patient material (i.e., skin biopsies) of 24 previously iden-
tified cases. Positive controls containing DNA from L. (L.) major
(culture) and a negative control void of DNA were included in
each assay reaction. Specificity was tested using a negative
control group consisting of 30 tissue-negative, six bacteria-
positive, seven fungi-positive, and two yeast-positive clinical
samples previously submitted to St. Vincent’s Hospital
(Table 1). Sensitivity was estimated using a series of 10-fold
dilutions of DNA from extracted L. (L.) major cultures to assess
the lowest detection threshold of each PCR assay. Reaction
templates corresponded to decreasing concentrations from
102 to 10−3 ng/μL DNA per PCR tube. The final concentrations
of the samples were 100 ng/μL, 20 ng/μL, 4 ng/μL, 0.8 ng/μL,
0.16 ng/μL, 0.032 ng/μL, 0.0064 ng/μL, and 0.00128 ng/μL.
Sequencing. For the purposes of sequencing, the entire
PCR product of 21 selected clinical samples was loaded onto
gels across multiple wells so that the maximum mass of PCR
product could be obtained for sequencing. The PCR products
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of the correct size were excised from the agarose gel using a
sterile scalpel blade. The PCR product was extracted from gel
slices using a QIAquick® Gel Extraction Kit (Cat. No. 28706;
QIAGEN, Hilden, Germany) following the manufacturer’s
protocol. A slightmodificationwasmade to the protocol at the
DNA elution stage in step nine of themanufacturer’s kit insert,
where 33 μL of ddH2Owas used instead of the recommended
50 μL. The concentration of DNA obtained from the gel slices
was quantitated using a Nanodrop® Spectrophotometer ND-
1000 (Thermo Fisher Scientific, Waltham, MA). All purified
PCRproductswere stored at−20Cuntil theywere shipped to
the service provider Macrogen (Seoul, South Korea), for se-
quencing. Sequencing was performed on an ABI 3730XL
capillary sequencer, twice in each forward and reverse di-
rection. An NCBI BLAST database was created on command
line using every available ND7 sequence as the query.
Virtual digestion of amplified ND7 gene sequences. In
silico modeling of the ND7 gene products was used to gen-
erate the predicted DNA fragments that would result from an
RFLP digestion. Additional sequences obtained from the
NCBI GenBank were included to generate a model containing
every available Leishmania ND7 gene sequence. Virtual di-
gests were performed using the Geneious software package,
version 11.0.2. Single digestions were performed with every
commercially available enzyme to assess the suitability for
certain restriction enzymes.
RFLP analysis of amplified ND7. Two restriction endo-
nucleases: HpyCH4IV and NlaIII (New England Biolabs, Hert-
fordshire, United Kingdom) were used to individually digest
the ND7 kDNA fragments. Polymerase chain reaction prod-
ucts (10 μL) were digested separately for each enzyme in a
final volume of 25 μL with the corresponding reaction buffers
and conditions summarized in Table 2. The restriction frag-
ments were subjected to electrophoresis in 3% agarose gel
containing GelRed Nucleic Acid Gel Stain Biotium for 2–3
hours and visualized underUV light using a LKBBromma2011
Macrovue Transilluminator.
Phylogenetic analysis. Phylogenetic trees were con-
structed from the DNA sequences to infer the evolutionary
relationships between the 21 clinical samples of Leishmania.
Multiple alignments were performed using the MUSCLE al-
gorithmic approach implemented in the Seaview software
package.35 Phylogenetic treeswere constructed usingPAUP*
version 4.0.36 Phylogenies were inferred using a heuristic
search under the parsimony criterion, which involved random
stepwise addition with tree bisection and reconnection (TBR)
branch swapping and 1,000 random replicates.37 Bootstrap
support for clade topologies was estimated following the
analysis of 1,000 pseudo-replicate datasets. Inter- and in-
traspecies similarities of theND7 regionwere calculated for 21
clinical isolates using MEGA software v.7.0.21.38
RESULTS
Variant calling. The number of SNPs and indels identified
between the various Leishmania species can be seen in
Table 3. As expected, species of the Viannia subgenus and
L. (L.) infantum and L. (L.) donovani exhibited very few poly-
morphisms when compared with one another. The L. (V.)
braziliensis and the L. (V.) peruviana maxicircle coding region
differed by 25 SNPs and three indels. L. (V.) guyanensis and L.
(V.) panamensis differed by 19 SNPs and seven indels,
whereas L. (L.) infantum and L. (L.) donovani differed by 125
SNPs and 13 indels. The distribution of variants called along
the maxicircle coding region identified ND7 gene as an ideal
candidate for the RFLP analysis of Leishmania. Supplemental
File 1 contains a list of the distribution and gene location of
SNPs when comparing the various Leishmania spp.
Application of the ND7 PCR assay to clinical samples.
The ability of the PCR assays to detect Leishmania infection in
clinical materials was tested with 24 positive samples sub-
mitted to the Department of Microbiology, St. Vincent’s Hos-
pital, Sydney, between 2004 and 2017 (Table 4). Among all
clinical isolates and cultured reference strains, specific am-
plification of an 800-bp fragment of the ND7 region was ob-
served. The lowest detection threshold of each PCR method
was equivalent to 0.032 ng/μL (Figure 2). No parasite DNA nor
PCR amplification was detected by the PCR assay in neither
the negative control where only water was used as the tem-
plate nor the negative control group of 45 tissues samples
containing commonly reported bacteria, fungi, and yeast
species.
In silico digestion and species identification by PCR-
RFLP of the amplified ND7 region in clinical samples. Six
hundred twenty-five commercially available enzymes were
assessed for their ability to discriminate between species of
the Leishmania genus. Following the analyses using the
software application Geneious, version 11.0.2, two enzymes,
NlaIII and HpyCH4IV, were selected for the subsequent di-
gestion of the ND7 amplicon. All 24 clinical samples found
positive by PCR amplification of the ND7 were further tested
TABLE 2
Reaction conditions for each restriction enzyme used for the ND7 PCR-RFLP
Enzyme (μL) Product source Recognition site Reaction buffer (μL) Reaction conditions
HpyCH4IV (1 μL) Helicobacter pylori CH4 59. . . A/C G T . . .39.39. . . T G C/A . . .59 1 × CutSmart® Buffer (2.5 μL) 2 hours at 37C
NlaIII (1 μL) Neisseria lactamica 59. . . C A T G/ . . .39 39. . . /G T A C . . .59 1 × CutSmart Buffer (2.5 μL) 2 hours at 37C
TABLE 1
List of bacterial and fungal species tested as a negative control group
Sample type Clinical sample (number of samples tested)
Negative Negative tissue samples (n = 30)
Bacteria Staphylococcus aureus (n = 1)
Staphylococcus epidermidis (n = 1)
Micrococcus luteus (n = 1)
Pseudomonas aeruginosa (n = 1)
Bacillus cereus (n = 1)
Escherichia coli (n = 1)
Yeast Candida albicans (n = 1)
Candida glabrata (n = 1)
Fungi Sporothrix schenckii (n = 1)
Fusarium sp. (n = 1)
Trichophyton mentagrophytes (n = 2)
Epidermophyton floccosum (n = 1)
Trichophyton rubrum (n = 1)
Aspergillus fumigatus (n = 1)
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by digestion with HpyCH4IV and NlaIII. The ND7 PCR-RFLP
was designed as a dual diagnostic assay, performing two
separate digestions simultaneously, using different enzymes
for eachassayona single clinical isolate. Themajor advantage
of digestion of theND7-PCRwith the restriction enzymeNlaIII
is that L. (V.) braziliensis can be differentiated from the L. (V.)
guyanensis/L. (V.) panamensis complex of the Viannia sub-
genus (Figure 3). The differentiation of L. (L.)major (OldWorld)
and L. (V.) guyanensis/L. (V.) panamensis complex (New
World) may cause difficulties if travel history is unknown, but
the concurrent digestion with the restriction enzyme Hpy-
CH4IV solves this problem (Figure 4). Digestion with NlaIII
gave the following fragments: L. (L.)major (598 and 251 bp), L.
(L.) tropica (344, 251, and 225 bp), L. (V.) braziliensis (557 and
186 bp), L. (V.) guyanensis/L. (V.) panamensis complex (557
and 251 bp), and L. (L.) donovani complex (305, 263, and
251bp) (Figure 3). DigestionwithHpyCH4IVgave the following
fragments: L. (L.) major (620, 119, and 98 bp), L. (L.) tropica
(350, 278, and 182 bp), L. (V.)braziliensis (428, 301, and 90bp),
L. (V.) guyanensis/L. (V.) panamensis complex (428, 311, and
104 bp), and L. (L.) donovani complex (428, 278, and 104 bp)
(Figure 4). Both NlaIII and HpyCH4IV were unable to differen-
tiate between L. (V.) guyanensis/L. (V.) panamensis and L. (L.)
donovani/L. (L.) infantum. However, subsequent sequencing
of the ND7 gene successfully resolved identification at the
species level between L. (L.) donovani and L. (L.) infantum.
Sequencing and phylogenetic tree analysis. Of the 21
samples selected for sequencing, five species of the L. (L.) and
L. (V.) were identified: L. (L.) major, L. (L.) tropica, L. (V.) bra-
ziliensis, L. (L.) infantum, and L. (V.) guyanensis/L. (V.) pan-
amensis complex (Table 4). The ND7 sequence was unable to
discriminate between L. (V.) guyanensis/L. (V.) panamensis
and is hereafter referred to as the L. (V.) guyanensis/L. (V.)
panamensis complex. From the heuristic search of the ND7,
the most parsimonious tree was found to be 304. Of the 844
characters analyzed under the parsimony optimality criterion,
634 characters were constant, 64 variable characters were
parsimony-uninformative, and a final 146 characters were
considered parsimony-informative. The evolutionary rela-
tionships showing the genetic distance between clinical iso-
lates of Leishmania is shown in Figure 5. In the inferred
phylogeny, all Leishmania clades corresponded to previous
classifications of the Leishmaniinae subfamily.18,39,40 Each
clinical isolate clustered according to their species-specific
identification, forming five distinct, monophyletic clades. In-
traspecies similarities of the ND7 region in isolates of L. (L.)
major, L. (L.) tropica, L. (V.) braziliensis, L. (L.) infantum, and L.
(V.) guyanensis/L. (V.) panamensis complex were 100%,
100%, 99.9%, 100%, and 98.6%, respectively (Figure 6). The
highest inter-species similarity was observed between the L.
(Viannia) subgenera, with 98% similarity between L. (V.) bra-
ziliensis and theL. (V.)guyanensis/L. (V.)panamensis complex.
DISCUSSION
Whereas previous cases of imported leishmaniasis into
Australia have been described (case studies 1–14)29,30, this
study reports an additional 10 cases imported throughout
2017 (case studies 15–24). Over the last two decades, a
multitude of diagnostic assays targeting various genes in-
cluding the ITS-1, Hsp70, antigen-encoding genes gp63 and
cpb, RNA polymerase II, and the N-acetylglucosamine-1-
phosphate transferase have been designed for the detection
and identification of Leishmania species.41–45 In the absence
of a globally accepted “gold standard” for diagnosis, the
downside of such an immense range of tests is that many of
these methods are obscurely used in very few or individual
laboratories throughout the world. Cited more than 185 times
in PubMed (viewed March 23, 2019), and used for the de-
tection and identification of various Leishmania species in 63
articles (Supplemental File 2), the ITS-1 remains the most
extensively used tool for the diagnosis of leishmaniasis. The
maindrawbackof the ITS-1asadiagnostic target is its inability
to distinguish between important species of the Viannia sub-
genus. The main aim of this study was to address the limita-
tions of the widely used ITS-1 PCR-RFLP and establish a
diagnostic PCR-RFLP assay that is capable of not only iden-
tifying the principal Leishmania spp. associated with clinical
leishmaniasis but also discriminating between species that
the ITS-1 cannot. The design of a PCR-RFLP targeting the
ND7 is a reliable and cost- and time-effective method that
does not require prior gel purification, making it an ideal can-
didate for the diagnosis and identification of the principal
Leishmania species.Using theND7PCR-RFLP,weprovide an
appraisal on the molecular epidemiology of previously im-
ported cases of leishmaniasis in Australia.
This study was limited by the spectrum of species that are
imported into Australia. Despite being only one of two conti-
nents free of endemic, clinically important Leishmania spp.,
cases of imported human leishmaniasis are rising at an ever-
increasing rate because of international travel, the influx of
immigrants, and military operations.29,30 This trend highlights
the difficulties present in diagnostics, particularly in non-
endemic areas where any species of Leishmania can be
imported, often from endemic areas where more than one
species is present (Figure 1).8 In addition, diagnosis based on
clinical symptoms in conjunction with area of travel is difficult
because several species can cause awide spectrumof clinical
TABLE 3
Number of single nucleotide polymorphisms (above diagonal) and indels (below diagonal) identified between the various Leishmania (L.) species
L. braziliensis L. peruviana L. guyanensis L. panamensis L. infantum L. donovani L. major L. amazonensis L. mexicana
L. braziliensis – 27 218 215 1,179 1,366 1,243 1,680 1,753
L. peruviana 3 – 226 226 1,178 1,365 1,253 1,675 1,753
L. guyanensis 25 27 – 21 1,425 1,444 1,268 1,402 1,381
L. panamensis 25 25 7 – 1,228 1,372 1,292 1,683 1,738
L. infantum 29 30 40 31 – 133 1,241 1,528 1,584
L. donovani 41 41 42 45 13 – 1,227 1,510 1,567
L. major 39 41 42 43 69 67 – 1,382 1,430
L. amazonensis 72 73 41 80 94 83 63 – 712
L. mexicana 76 81 42 77 101 108 57 71 –
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manifestations such as localized CL and MCL.46 The etio-
logical agents primarily responsible for the imported cases of
human leishmaniasis in Australia are typically members of the
species that either cannot be differentiated by the ITS-1 PCR-
RFLP reported in Schönian et al.8 This includes the L. (V.)
braziliensis/L. (V.) panamensis/L. (V.) guyanensis complex or
those that can cause difficulties if not run simultaneously
alongside one another (L. [L.] donovani/L. [L.] infantum). As a
result of this epidemiological trend, we set out to design a
universal diagnostic PCR method that combines sensitivity
and is capable of species-specific differentiation through a
combination of both RFLP and sanger sequencing.
Over the last 10 years, PCR-RFLP as a diagnostic method
has become the method of choice to detect and identify the
leishmaniasis infective species from imported cases in Aus-
tralia. Important advantagesof PCR-RFLP for genetic analysis
and species identification include its relative inexpensiveness
and less laborious method with greater sensitivity than that of
the traditional microscopic detection of parasites in culture.
The ND7 PCR-RFLP offers a highly sensitive technique,
allowing the characterization of Old World and New World
Leishmania species in clinical infections. This is crucial to not
only inform the most effective treatment but also provide
valuable epidemiology on the distribution of Leishmania spe-
cies being imported into Australia. In a clinical setting, the
disadvantage of RFLP analysis is the risk of contamination by
amplicons resulting in false-positive results.10 However, the
use of two separate enzymes (NlaIII and HpyCH4IV) that re-
quire identical assay conditions including reagents, reaction
volume, digestion temperature, and time addresses this
drawback. These enzymes were chosen for their ability to
generate an easily distinguishable restriction pattern, low
cost, and availability, and that they can be run simultaneously,
requiring identical assay conditions. In addition, NlaIII was
chosen because of its specificity for L. (V.) braziliensis and
HpyCH4IV was chosen for its ability to distinguish between
FIGURE 3. PCR-RFLP analysis of Leishmania species with the restriction enzyme NlaIII. Samples were run alongside a 50-bp molecular weight
marker.Comparisonof thebandpatternsof theDNA fragmentsgenerated from theNlaIII digestionof in silico, culture, andclinical isolates.Digestion
withNlaIII can successfully differentiate between the extremely closely related Leishmania (Viannia) (L. [V.]) braziliensis and L. (V.) guyanensis/L. (V.)
panamensis complex of the Viannia subgenus, which is extremely important in a clinical settingwhere treatment outcome can vary greatly between
these two species.
FIGURE 2. DNA electrophoresis of sensitivity test ofND7-PCR of Leishmania (Leishmania)major. Sampleswere run alongside a 50-bpmolecular
weight marker (Bioline). A negative control, void of DNA is marked by the “N” lane. The lanes labeled 1–8 correspond to the concentrations 100 ng/
μL, 20 ng/μL, 4 ng/μL, 0.8 ng/μL, 0.16 ng/μL, 0.032 ng/μL, 0.0064 ng/μL, and 0.00128 ng/μL, respectively. The lowest detection threshold of the
ND7-PCR was equivalent to 0.032 ng/μl (lane 6).
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Old World and New World species of the subgenus L. (L.). By
ensuring that the same fingerprinting identification is reached
from two separate digestions run concurrently, the restriction
digest of ND7-PCR amplicons with NlaIII and HpyCH4IV
provide a robust, 2-fold diagnosis. Thus, in a clinical setting, it
requires minimal effort to perform a simultaneous dual re-
striction analysis that is sufficient to distinguish between the
medically relevant Leishmania species being imported into
Australia. In addition, the ND7 as a biomarker allows for ad-
ditional species-specific identification through sequencing,
providing greater support for the classification of clinical iso-
lates. If a PCR product can be obtained from either the ITS1-
PCR or ND7-PCR, the whole PCR diagnosis (DNA extraction,
PCR and RFLP) can be performed in 2–2.5 days. However, if
identification cannot be resolved at a species level, se-
quencing of the ND7-PCR (purification, transportation, and
Sanger sequencing) will require an additional 3–4 days com-
pared with ITS1 sequencing (molecular cloning, trans-
portation, and Sanger sequencing) that requires an additional
11–14 days.
In the present study, CL was the most common clinical
manifestation described (n = 23) (Table 4). As previously re-
ported by Roberts et al.,29 lesions on the legs and arms were
the most common presentation in patients. No cases of MCL
were observed in the 10 cases reported in 2017. Five species/
complexes of Leishmaniawere identified; two L. (L.)major, six
L. (L.) tropica, seven L. (V.) braziliensis, five L. (V.) guyanensis/
L. (V.) panamensis complex and four L. (L.) infantum. From our
analyses, the infective species of five case studies previously
identified as belonging to the generic L. (V.) braziliensis
complex have now been correctly reclassified as L. (V.)
guyanensis/L. (V.) panamensis complex. Despite the ND7
PCR-RFLP diagnostic assay being insufficient to discriminate
between L. (L.) donovani and L. (L.) infantum, species identity
was successfully resolved through sequencing and the four
isolates previously identified as belonging to the L. (L.)
donovani complex revealed a 100%BLAST identity with L. (L.)
infantum. One specimen (case study 3) that could not be
specifically identified because of the presence of a very weak
positive PCR product resulting in an ambiguous restriction
FIGURE 5. Inferred evolutionary relationships showing genetic dis-
tance between clinical isolate of imported cases of leishmaniasis. The
structure of this tree was inferred from DNA sequence data using the
parsimony criterion with 1,000 bootstrap replicates. The scale bar
represents the number of nucleotide substitutions per site. Each
clinical isolate clustered according to their species-specific identifi-
cation, forming five distinct, monophyletic clades.
FIGURE 4. PCR-RFLP analysis of Leishmania species with the restriction enzyme HpyCH4IV. Samples were run alongside a 50-bp molecular weight
marker. Comparison of the band patterns of the DNA fragments generated from theHpyCH4IV digestion of in silico, culture, and clinical isolates. Digestion
with HpyCH4IV can successfully differentiate between NewWorld and Old World Leishmania species isolated from both culture and clinical specimens.
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pattern was identified as L. (V.) braziliensis. From the 2017
specimens, L. (L.) tropica was the most common species
identified, which coincides with the patients’ travel history
where all L. (L.) tropica-infected patients were civilian im-
migrants from Afghanistan or the Middle East. The vast
majority of travelers from the 2017 cohort examined in this
studywere infectedwith species of the Leishmania (Viannia)
subgenus, coinciding with most patients having reported
previous travel to Leishmania endemic regions of South
America.
The taxonomic status of L. (V.) guyanensis and L. (V.)
panamensis has often been debated, with reports ques-
tioning the validity of the division of these complexes into
two distinct species.47–49 Together both PCR-RFLP and
sequencing of the ND7 gene do not possess the discrimi-
natory power to discern between species of the L. (V.)
guyanensis/L. (V.) panamensis complex. Variant calling
identified only 26 variants between the two species (Table 3)
and from our previous analyses on the coding region of the
Leishmaniinae maxicircle, we demonstrated that L. (V.)
guyanensis/L. (V.) panamensis are separated by a genetic
distance of only 0.001. Considering their extremely close
genetic relatedness in context of the previously published
concerns surrounding these species, it is important to ac-
knowledge the outstanding questions surrounding the
validity of these Viannia parasites and whether these par-
asites warrant speciation as distinct organisms or is merely
genomic variability within a sole species. However, the
greatest intraspecies divergence was seen within species
of the Viannia subgenus (Figure 6). This diversity is reflected
in Figure 5, where the phylogenetic analysis revealed two
clusters within the L. (V.) guyanensis/L. (V.) panamensis
complex isolates and two within the L. (V.) braziliensis iso-
lates. No correlations were seen between the intraspecies
diversity through SNPs and geographic distribution of the
species. Clinical isolates of the L. (L.) infantum, L. (L.)major,
and L. (L.) tropica case studies showed no diversity and
formed independent, monophyletic clades with 100%
bootstrap confidence.
Despite the recent appraisal, in which Leishmania (L.)
infantum and Leishmania (L.) donovaniwere recognized as the
only species of the L. (L.) donovani complex,50 issues still
surround the taxonomic status of this complex. The Leish-
mania donovani complex have a largely discrete geographic
FIGURE 6. Levels of intra- and inter-species mean similarities of Leishmania spp. (A) Intraspecies mean similarities for Leishmania species from
leishmaniasis cases based on the ND7 region sequence. Intraspecies similarities of the ND7 region in isolates of Leishmania (Viannia) (L. [V.])
guyanensis/L. (V.) panamensis complex, L. (V.) braziliensis, Leishmania (Leishmania) (L. [L.]) infantum, L. (L.)major, and L. (L.) tropica were 98.6%,
99.9%, 100%, 100%, and 100%, respectively. (B) Inter-species mean similarities for Leishmania species from leishmaniasis cases based on the
ND7 region sequence. The greatest inter-species similarity was seen between L. (V.) braziliensis and the L. (V.) guyanensis/L. (V.) panamensis
complex with 98% similarity.
598 KAUFER AND OTHERS
distribution; L. (L.) donovani in the Old World is predominately
found in East Africa, India, and parts of the Middle East, and
L. (L.) infantum in both the Old World and New World, which
is found in Europe, North Africa, and South and Central
America.50,51 However, the genetic diversity of these two
species are the cause for complications regarding the clas-
sification of these parasites. In the past, phylogenetic analy-
ses based on insufficient taxonomicmarkers that were unable
to detect the diversity (if any) between these extremely similar
species have been the main source for confusion. Neverthe-
less, the use of a large dataset based on the entire coding
region of the maxicircle only detected few DNA polymor-
phisms (Table 3) between L. (L.) donovani and L. (L.) infantum,
separated by a genetic divergence of only 0.007.26 As such,
theND7PCR-RFLPdoesnot have thediscriminatory power to
delineate the boundary between these two species. However,
subsequent sequencing of the ND7 amplicons did show that
the ND7-PCR was capable of resolving these species, with
100% BLAST identity of four clinical samples aligning with L.
(L.) infantum. Despite this, treatment for L. (L.) donovani and L.
(L.) infantum is the same, with amphotericin B and miltefosine
being the first-line treatment option of choice.52,53 Thus, the
ability of theND7-RFLP to identify theL. (L.)donovani complex
is sufficient for the administration of correct treatment.
The need for accurate speciation in clinical cases of leish-
maniasis is of paramount importance, particularly when
dealing with species of the Viannia subgenus. Leishmania
(Viannia) species of the NewWorld can lead to diverse clinical
presentations and as such often have a diverse and un-
predictable response to treatment.54 Previous reports have
demonstrated a strong correlation between inappropriately
treated CL forms of the disease and the subsequent occur-
rence of MCL for both L. (V.) braziliensis and L. (V.)
guyanensis.55,56 Pentavalent antimonials are the most fre-
quently used first-line treatment for both CL and VL.52 How-
ever, the therapeutic response to antimonials in patients with
CL is highly dependent on the L. (Viannia) etiological agent
causing the infection.57 Romero et al.57 demonstrated that
patients infected with L. (V.) guyanensis had a higher failure
rate in response to treatment with meglumine antimoniate
than L. (V.) braziliensis, and Francesconi et al.54 also showed
that fluconazole was not efficacious against CL caused by L.
(V.) guyanensis in adult men. In addition, the Viannia species
are susceptible not only to the drug of choice but also to the
route of administration, with Christen et al.58 demonstrating
that an intramuscular dosage of pentamidine isethionate in L.
(V.) guyanensis–infected patients increased the risk of treat-
ment failure. Thus, it is essential for clinicians to have the tools
available that allow the correct differentiation between L. (V.)
braziliensis and L. (V.) guyanensis, ensuring the administration
of the most effective first-line treatment with the correct
course of chemotherapeutic drugs. The ND7 PCR-RFLP
provides a species-specific approach that can not only iden-
tify the various causative species across the Leishmania ge-
nus but also differentiate L. (V.) braziliensis from the L. (V.)
guyanensis/L. (V.) panamensis complex. Use of this finger-
printing technology in clinical settings may therefore ultimately
lead to higher cure rates and lower costs due to side effects
from the administration of highly toxic ineffective drugs.
To conclude, we describe a dual-analysis PCR-RFLP ca-
pable of not only identifying the principal species of both New
World and Old World Leishmania but also possessing the
discriminatory power to differentiate between the extremely
closely related species of the L. (Viannia) subgenus. Thus,
superior to the extensively used ITS1PCR-RFLPdescribed by
Schönian et al.,8 the PCR-RFLP targeting theND7 gene of the
kDNA can be applied to not only imported cases of leish-
maniasis in Australia but also in other endemic and non-
endemic areaswheremore thanone specie ismost likely to be
present. The diagnostic method combines the sensitivity to
detectLeishmania in extracted clinicalmaterials and the ability
to fingerprint and identify the clinically important species. In
this study, we provide an appraisal on 14 previously reported
case studies between 2008 and 2014 and present data on the
molecular identification and epidemiology of an additional 10
cases of imported leishmaniasis in Australia. Over a 1-year
period in 2017, L. (L.) tropica was the most common species
identified from civilian immigrants and L. (Viannia) species
were the infective species for the vast majority or travelers.
These results demonstrate the continuing trend in risk factor,
country of infection, clinical presentation, and the pre-
dominant causative species in imported cases of leishmani-
asis. Although leishmaniasis is not presently a notifiable
disease in Australia, the number of new cases reported at
SydPath has increased considerably over the last 10 years at
an alarming rate. The results highlight the need for providing
Australian clinicians with the tools specific for diagnosing and
determining the causative Leishmania species.
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Ramı́rez JD, 2014. Identification of six New World Leishmania
species through the implementation of a high-resolution melt-
ing (HRM) genotyping assay. Parasit Vectors 7: 501.
AUSTRALIAN IMPORTED CLINICAL INFECTIONS OF LEISHMANIA 599
7. HerreraG,HernandezC,AyalaMS,FlorezC,TeheranAA,Ramirez
JD, 2017. Evaluation of a multilocus sequence typing (MLST)
scheme for Leishmania (Viannia) braziliensis and Leishmania
(Viannia) panamensis in Colombia. Parasit Vectors 10: 236.
8. Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig H,
PresberW, JaffeCL, 2003. PCRdiagnosis and characterization
of Leishmania in local and imported clinical samples. Diagn
Microbiol Infect Dis 47: 349–358.
9. Van der AuweraG, Ravel C, Verweij JJ, Bart A, SchonianG, Felger
I, 2014. Evaluation of four single-locus markers for Leishmania
species discrimination by sequencing. J Clin Microbiol 52:
1098–1104.
10. Sagi O, Berkowitz A, Codish S, Novack V, Rashti A, Akad F,
Shemer-Avni Y, 2017. Sensitive molecular diagnostics for cu-
taneous leishmaniasis. Open Forum Infect Dis 4: ofx037.
11. McManus DP, Bowles J, 1996. Molecular genetic approaches to
parasite identification: their value in diagnostic parasitology
and systematics. Int J Parasitol 26: 687–704.
12. Mouttaki T, Morales-Yuste M, Merino-Espinosa G, Chiheb S,
Fellah H, Martin-Sanchez J, Riyad M, 2014. Molecular di-
agnosis of cutaneous leishmaniasis and identification of the
causative Leishmania species in Morocco by using three PCR-
based assays. Parasit Vectors 7: 420.
13. Pourmohammadi B, MotazedianM, HatamG, Kalantari M, Habibi
P, Sarkari B, 2010. Comparison of three methods for diagnosis
of cutaneous leishmaniasis. Iran J Parasitol 5: 1–8.
14. Sundar S, Rai M, 2002. Laboratory diagnosis of visceral leish-
maniasis. Clin Diagn Lab Immunol 9: 951–958.
15. Wilson SM, 1995. DNA-based methods in the detection of
Leishmania parasites: field applications and practicalities. Ann
Trop Med Parasitol 89: 95–100.
16. Reithinger R, Dujardin JC, 2007. Molecular diagnosis of leish-
maniasis: current status and future applications. J Clin Micro-
biol 45: 21–25.
17. Kaufer A, Ellis J, Stark D, Barratt J, 2017. The evolution of trypa-
nosomatid taxonomy. Parasit Vectors 10: 287.
18. Barratt J, Kaufer A, Peters B, Craig D, Lawrence A, Roberts T, Lee
R, McAuliffe G, Stark D, Ellis J, 2017. Isolation of novel
trypanosomatid, Zelonia australiensis sp. nov. (Kinetoplastida:
Trypanosomatidae) provides support for a Gondwanan origin
of dixenous parasitism in the Leishmaniinae. PLoS Negl Trop
Dis 11: e0005215.
19. Mugasa CM, Laurent T, Schoone GJ, Basiye FL, Saad AA, el Safi
S,KagerPA,SchalligH, 2010. Simplifiedmolecular detectionof
Leishmania parasites in various clinical samples from patients
with leishmaniasis. Parasit Vectors 3: 13.
20. Lin RH, Lai DH, Zheng LL, Wu J, Lukes J, Hide G, Lun ZR, 2015.
Analysis of themitochondrial maxicircle of Trypanosoma lewisi,
a neglected human pathogen. Parasit Vectors 8: 665.
21. Telleria J, Lafay B, Virreira M, Barnabe C, Tibayrenc M, Svoboda
M, 2006. Trypanosoma cruzi: sequence analysis of the variable
region of kinetoplast minicircles. Exp Parasitol 114: 279–288.
22. Flegontov PN, Zhirenkina EN, Gerasimov ES, Ponirovsky EN,
Strelkova MV, Kolesnikov AA, 2009. Selective amplification of
maxicircle classes during the life cycle of Leishmania major.
Mol Biochem Parasitol 165: 142–152.
23. Gerasimov ES, Gasparyan AA, Litus IA, Logacheva MD,
Kolesnikov AA, 2017. Minicircle kinetoplast genome of insect
trypanosomatid Leptomonas pyrrhocoris. Biochemistry (Mosc)
82: 572–578.
24. Simpson L, Douglass SM, Lake JA, Pellegrini M, Li F, 2015.
Comparison of the mitochondrial genomes and steady state
transcriptomes of two strains of the trypanosomatid parasite,
Leishmania tarentolae. PLoS Negl Trop Dis 9: e0003841.
25. Yatawara L, Le TH, Wickramasinghe S, Agatsuma T, 2008. Max-
icircle (mitochondrial) genome sequence (partial) of Leishmania
major: gene content, arrangement and composition compared
with Leishmania tarentolae. Gene 424: 80–86.
26. Kaufer A, Barratt J, Stark D, Ellis J, 2019. The complete coding
region of the maxicircle as a superior phylogenetic marker for
exploring evolutionary relationships between members of the
Leishmaniinae. Infect Genet Evol 70: 90–100.
27. Akhoundi M et al., 2017. Leishmania infections: molecular targets
and diagnosis.Mol Asp Med 57: 1–29.
28. BensoussanE,NasereddinA, JonasF, Schnur LF, JaffeCL, 2006.
Comparison of PCR assays for diagnosis of cutaneous leish-
maniasis. J Clin Microbiol 44: 1435–1439.
29. Roberts T, Barratt J, Sandaradura I, LeeR, Harkness J,Marriott D,
Ellis J, Stark D, 2015. Molecular epidemiology of imported
cases of leishmaniasis in Australia from 2008 to 2014. PLoS
One 10: e0119212.
30. Stark D, van Hal S, Lee R, Marriott D, Harkness J, 2008. Leish-
maniasis, an emerging imported infection: report of 20 cases
from Australia. J Travel Med 15: 351–354.
31. Chouihi E, Amri F, Bouslimi N, Siala E, Selmi K, Zallagua N, Ben
Abdallah R, Bouratbine A, Aoun K, 2009. Cultures on NNN
medium for the diagnosis of leishmaniasis. Pathol Biol (Paris)
57: 219–224.
32. Li H, Durbin R, 2009. Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.
33. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis
ER, Weinstock GM, Wilson RK, Ding L, 2009. VarScan: variant
detection in massively parallel sequencing of individual and
pooled samples. Bioinformatics 25: 2283–2285.
34. Li H, Handsaker B,Wysoker A, Fennell T, Ruan J, Homer N,Marth
G, Abecasis G, Durbin R; 1000 Genome Project Data Pro-
cessing Subgroup, 2009. The sequence alignment/map format
and SAMtools. Bioinformatics 25: 2078–2079.
35. Gouy M, Guindon S, Gascuel O, 2010. SeaView version 4: a
multiplatform graphical user interface for sequence alignment
and phylogenetic tree building.Mol Biol Evol 27: 221–224.
36. Swofford DL, 1993. PAUP–a computer-program for phylogenetic
inference using maximum parsiomy. J Gen Physiol 102: A9.
37. Swofford DL, Bell CD, 2017. PAUP Manual Available at: http://
phylosolutions.com/paup-documentation/paupmanual.pdf.
Accessed July 17, 2018.
38. Kumar S, Stecher G, Tamura K, 2016. MEGA7: molecular evolu-
tionary genetics analysis version 7.0 for bigger datasets. Mol
Biol Evol 33: 1870–1874.
39. EspinosaOA, SerranoMG,CamargoEP, TeixeiraMMG,ShawJJ,
2018. An appraisal of the taxonomy and nomenclature of try-
panosomatids presently classified as Leishmania and Endo-
trypanum. Parasitology 145: 430–442.
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